Otezla is the first and only oral therapy approved across all severities of adult plaque psoriasis SEE THE DATA

Plaque Psoriasis
3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
Otezla is the first and only oral therapy approved across all severities of adult plaque psoriasis SEE THE DATA
Actual Otezla patient. 1 Individual results may vary.
*PASI-49.7 response: A 49.7% reduction in a patient’s PASI score. 1
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
†PASI-52 response: A 52% reduction in a patient’s PASI score. 1
Actual Otezla patient. 1 Individual results may vary.
‡PASI-62.5 response: A 62.5% reduction in a patient’s PASI score. 1
§PASI-72 response: A 72% reduction in a patient’s PASI score. 1
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
**PASI-63 response: A 63% reduction in a patient’s PASI score. 1
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
††PASI-69 response: A 69% reduction in a patient’s PASI score. 1
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
‡‡PASI-70 response: A 70% reduction in a patient’s PASI score. 1
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
§§PASI-75 response: A 75% reduction in a patient’s PASI score. 1
Actual Otezla patient. 1 Individual results may vary.
***PASI-76.5 response: A 76.5% reduction in a patient’s PASI score. 1
†††PASI-90 response: A 90% reduction in a patient’s PASI score. 1
Actual Otezla patient. 1 Images are not reflective of NAPSI score. Individual results may vary.
Actual Otezla patient. 1 Images are not reflective of NAPSI score. Individual results may vary.
Actual Otezla patient. 1 Individual results may vary.
‡‡‡PASI-80 response: An 80% reduction in a patient’s PASI score. 1
Actual Otezla patient. 1 Individual results may vary.
Actual clinical trial patient from ESTEEM. 1 Individual results may vary.
§§§PASI-85 response: An 85% reduction in a patient’s PASI score. 1
Actual clinical trial patient from STYLE. 1 Individual results may vary.
Actual clinical trial patient from STYLE. 1 Individual results may vary.
Actual clinical trial patient from STYLE. 1 Individual results may vary.
NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index; ScPGA, Scalp Physician Global Assessment.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Reference: 1. Data on file, Amgen Inc.